SOHO Italy 2025 | The evolving management of Hodgkin lymphoma: a US perspective

It was my pleasure to be able to present this year at the SOHO meeting about how I manage Hodgkin lymphoma in the United States. It certainly is a rapidly evolving treatment paradigm, particularly with the results from the S1826 study that were reported last year in the New England Journal of Medicine. In that study patients were randomized to nivolumab AVD versus the then current standard of care, brentuximab plus AVD, and there was a clear progression-free survival benefit to the nivolumab AVD, so that has become our widely used frontline therapy for patients with newly diagnosed advanced-stage Hodgkin lymphoma. We’re still figuring out how to incorporate checkpoint inhibitors into the frontline therapy of early-stage Hodgkin lymphoma patients in the frontline. In the relapsed setting, salvage regimens that incorporate the checkpoint inhibitors nivolumab or pembrolizumab remain the most commonly used regimens. In my own practice, I often use the brentuximab plus nivolumab regimen or pembrolizumab with the GVD chemo regimen for salvage therapy, and then take patients on to autologous stem cell transplant if they respond well to their salvage regimen. But the use of those salvage regimens containing the checkpoint inhibitors will need to evolve in the setting of the nivolumab AVD, which has become our common first-line treatment.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.